<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084196</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2021001502</org_study_id>
    <nct_id>NCT05084196</nct_id>
  </id_info>
  <brief_title>Melatonin for Prevention of Kidney Injury</brief_title>
  <official_title>Melatonin for the Prevention of Antibiotic Associated Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of melatonin for the prevention of&#xD;
      antibiotic associated acute kidney injury in hospitalized patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consenting subjects meeting inclusion and exclusion will be randomized to receive melatonin 5&#xD;
      mg daily or a matching placebo. Study subjects will be followed for the duration of&#xD;
      hospitalization or discontinuation of broad spectrum antibiotics (vancomycin plus&#xD;
      piperacillin/tazobactam). The primary outcome and secondary outcomes will be evaluated by the&#xD;
      study team.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2023</start_date>
  <completion_date type="Anticipated">January 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>From date of randomization until the date of first documented acute kidney injury or date of antibiotic discontinuation, whichever came first, assessed up to 28 days</time_frame>
    <description>Acute kidney injury will be defined as an increase in sCr from baseline of &gt;/= 0.3 mg/dL or a &gt;/= 50% increase from baseline.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Melatonin plasma trough concentration</measure>
    <time_frame>Days 3, 5, and 7</time_frame>
    <description>Evaluate the steady state plasma trough concentration of melatonin</description>
  </other_outcome>
  <other_outcome>
    <measure>Piperacillin/tazobactam plasma trough concentration</measure>
    <time_frame>Days 3, 5, and 7</time_frame>
    <description>Evaluate the steady state plasma trough concentration of piperacillin/tazobactam</description>
  </other_outcome>
  <other_outcome>
    <measure>Vancomycin plasma Area Under the Curve (AUC)</measure>
    <time_frame>Days 3, 5, and 7</time_frame>
    <description>Evaluate the steady state plasma AUC of vancomycin</description>
  </other_outcome>
  <other_outcome>
    <measure>Association between Kidney Injury Molecule-1 (KIM-1) and serum creatinine</measure>
    <time_frame>Days 3, 5, and 7</time_frame>
    <description>Measure KIM-1 in plasma and urine and evaluate discordance between serum creatinine.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitochondrial stress assessment via extracellular flux analysis to measure oxygen consumption rate of cells</measure>
    <time_frame>Days 1 and 3</time_frame>
    <description>Evaluate mitochondrial stress in peripheral blood mononuclear cells from a subset of subjects in each group. In addition, mitochondrial stress will be evaluated on day 3 in a subset in the melatonin group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine mitochondrial DNA copy number</measure>
    <time_frame>Days 1, 3, 5, and 7</time_frame>
    <description>Measure mitochondrial DNA (mtDNA) in urine samples using polymerase chain reaction (PCR).</description>
  </other_outcome>
  <other_outcome>
    <measure>Fold-change in NRF-2 gene expression in peripheral blood mononuclear cells</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>Measure gene expression level at baseline and then on day 5 (or last day of study if earlier) using polymerase chain reaction (PCR) and compare the fold-change from baseline between groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with NRF2 DNA single nucleotide polymorphisms</measure>
    <time_frame>Day 1</time_frame>
    <description>Determination of the number of individuals with NRF2 DNA single nucleotide polymorphisms in the study population and compare the incidence of primary outcome in those with and without polymorphisms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with KEAP1 DNA single nucleotide polymorphisms</measure>
    <time_frame>Day 1</time_frame>
    <description>Determination of the number of individuals with KEAP1 DNA single nucleotide polymorphisms in the study population and compare the incidence of primary outcome in those with and without polymorphisms.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Adverse Drug Event</condition>
  <arm_group>
    <arm_group_label>Melatonin Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin 5 mg capsule by mouth at bedtime for the duration of hospitalization or discontinuation of broad spectrum antibiotics, whichever comes first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule by mouth at bedtime for the duration of hospitalization or discontinuation of broad spectrum antibiotics, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Melatonin 5 mg capsule by mouth at bedtime</description>
    <arm_group_label>Melatonin Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Capsule</intervention_name>
    <description>Placebo capsule by mouth at bedtime</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Aged 18 to 65 years&#xD;
&#xD;
          -  Currently prescribed vancomycin and piperacillin/tazobactam with the presumption that&#xD;
             therapy will be continued for at least 3 days based on a review of subject status.&#xD;
             Because of the critical nature of starting empiric broad-spectrum antibiotics, we will&#xD;
             allow one dose of the antibiotic combination before consent and enrollment. This&#xD;
             strategy is necessary for the ethical conduct of the study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Estimated creatinine clearance &lt; 30 mL/min&#xD;
&#xD;
          -  Liver impairment (liver enzymes &gt; 3 times upper limit)&#xD;
&#xD;
          -  Any history of allergy or contraindication to melatonin&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Requiring vasopressors&#xD;
&#xD;
          -  Requiring mechanical ventilation&#xD;
&#xD;
          -  History of acute kidney injury in the past 30 days&#xD;
&#xD;
          -  Inability to take oral medications&#xD;
&#xD;
          -  Clinical evidence of significant unstable or uncontrolled illness which, in the&#xD;
             opinion of the research team, could confound the results of the study or put the&#xD;
             patient at undue risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luigi Brunetti, PhD</last_name>
    <phone>908-595-2645</phone>
    <email>luigi.brunetti@rutgers.edu</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Luigi Brunetti, PharmD, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

